Cosmos Health Inc. (COSM)
| Previous Close | 0.6699 |
| Open | 0.6800 |
| Bid | 0.6451 x 100 |
| Ask | 0.7050 x 100 |
| Day's Range | 0.6500 - 0.6950 |
| 52 Week Range | 0.4680 - 4.0000 |
| Volume | |
| Avg. Volume | 274,309 |
| Market Cap | 11.41M |
| Beta (5Y Monthly) | 2.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K
CHICAGO, IL / ACCESSWIRE / April 19, 2024 /Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical ...
- ACCESSWIRE
Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform
CHICAGO, IL / ACCESSWIRE / March 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical ...
- ACCESSWIRE
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market
CHICAGO, IL / ACCESSWIRE / March 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical ...
